Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Paz, Katelyn, Flynn, Ryan, Du, Jing, Qi, Jun, Luznik, Leo, Maillard, Ivan, MacDonald, Kelli P., Hill, Geoffrey R., Serody, Jonathan S., Murphy, William J., Sage, Peter T., Sharpe, Arlene H., Miklos, David, Cutler, Corey S., Koreth, John, Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Bradner, James E., Melnick, Ari M., Blazar, Bruce R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318432/
https://ncbi.nlm.nih.gov/pubmed/30279226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-839993
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi